Fibroblast Growth Factor Receptor 1 Drives the Metastatic Progression of Prostate Cancer
Copyright © 2021 The Author(s). Published by Elsevier B.V. All rights reserved..
BACKGROUND: No curative therapy is currently available for metastatic prostate cancer (PCa). The diverse mechanisms of progression include fibroblast growth factor (FGF) axis activation.
OBJECTIVE: To investigate the molecular and clinical implications of fibroblast growth factor receptor 1 (FGFR1) and its isoforms (α/β) in the pathogenesis of PCa bone metastases.
DESIGN, SETTING, AND PARTICIPANTS: In silico, in vitro, and in vivo preclinical approaches were used. RNA-sequencing and immunohistochemical (IHC) studies in human samples were conducted.
OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: In mice, bone metastases (chi-square/Fisher's test) and survival (Mantel-Cox) were assessed. In human samples, FGFR1 and ladinin 1 (LAD1) analysis associated with PCa progression were evaluated (IHC studies, Fisher's test).
RESULTS AND LIMITATIONS: FGFR1 isoform expression varied among PCa subtypes. Intracardiac injection of mice with FGFR1-expressing PC3 cells reduced mouse survival (α, p < 0.0001; β, p = 0.032) and increased the incidence of bone metastases (α, p < 0.0001; β, p = 0.02). Accordingly, IHC studies of human castration-resistant PCa (CRPC) bone metastases revealed significant enrichment of FGFR1 expression compared with treatment-naïve, nonmetastatic primary tumors (p = 0.0007). Expression of anchoring filament protein LAD1 increased in FGFR1-expressing PC3 cells and was enriched in human CRPC bone metastases (p = 0.005).
CONCLUSIONS: FGFR1 expression induces bone metastases experimentally and is significantly enriched in human CRPC bone metastases, supporting its prometastatic effect in PCa. LAD1 expression, found in the prometastatic PCa cells expressing FGFR1, was also enriched in CRPC bone metastases. Our studies support and provide a roadmap for the development of FGFR blockade for advanced PCa.
PATIENT SUMMARY: We studied the role of fibroblast growth factor receptor 1 (FGFR1) in prostate cancer (PCa) progression. We found that PCa cells with high FGFR1 expression increase metastases and that FGFR1 expression is increased in human PCa bone metastases, and identified genes that could participate in the metastases induced by FGFR1. These studies will help pinpoint PCa patients who use fibroblast growth factor to progress and will benefit by the inhibition of this pathway.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:5 |
|---|---|
| Enthalten in: |
European urology oncology - 5(2022), 2 vom: 13. Apr., Seite 164-175 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Labanca, Estefania [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 12.05.2022 Date Revised 31.05.2022 published: Print-Electronic CommentIn: Eur Urol. 2022 Apr;81(4):431. - PMID 35031159 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.euo.2021.10.001 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM333122445 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM333122445 | ||
| 003 | DE-627 | ||
| 005 | 20231225221006.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.euo.2021.10.001 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1110.xml |
| 035 | |a (DE-627)NLM333122445 | ||
| 035 | |a (NLM)34774481 | ||
| 035 | |a (PII)S2588-9311(21)00182-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Labanca, Estefania |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Fibroblast Growth Factor Receptor 1 Drives the Metastatic Progression of Prostate Cancer |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.05.2022 | ||
| 500 | |a Date Revised 31.05.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Eur Urol. 2022 Apr;81(4):431. - PMID 35031159 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 The Author(s). Published by Elsevier B.V. All rights reserved. | ||
| 520 | |a BACKGROUND: No curative therapy is currently available for metastatic prostate cancer (PCa). The diverse mechanisms of progression include fibroblast growth factor (FGF) axis activation | ||
| 520 | |a OBJECTIVE: To investigate the molecular and clinical implications of fibroblast growth factor receptor 1 (FGFR1) and its isoforms (α/β) in the pathogenesis of PCa bone metastases | ||
| 520 | |a DESIGN, SETTING, AND PARTICIPANTS: In silico, in vitro, and in vivo preclinical approaches were used. RNA-sequencing and immunohistochemical (IHC) studies in human samples were conducted | ||
| 520 | |a OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: In mice, bone metastases (chi-square/Fisher's test) and survival (Mantel-Cox) were assessed. In human samples, FGFR1 and ladinin 1 (LAD1) analysis associated with PCa progression were evaluated (IHC studies, Fisher's test) | ||
| 520 | |a RESULTS AND LIMITATIONS: FGFR1 isoform expression varied among PCa subtypes. Intracardiac injection of mice with FGFR1-expressing PC3 cells reduced mouse survival (α, p < 0.0001; β, p = 0.032) and increased the incidence of bone metastases (α, p < 0.0001; β, p = 0.02). Accordingly, IHC studies of human castration-resistant PCa (CRPC) bone metastases revealed significant enrichment of FGFR1 expression compared with treatment-naïve, nonmetastatic primary tumors (p = 0.0007). Expression of anchoring filament protein LAD1 increased in FGFR1-expressing PC3 cells and was enriched in human CRPC bone metastases (p = 0.005) | ||
| 520 | |a CONCLUSIONS: FGFR1 expression induces bone metastases experimentally and is significantly enriched in human CRPC bone metastases, supporting its prometastatic effect in PCa. LAD1 expression, found in the prometastatic PCa cells expressing FGFR1, was also enriched in CRPC bone metastases. Our studies support and provide a roadmap for the development of FGFR blockade for advanced PCa | ||
| 520 | |a PATIENT SUMMARY: We studied the role of fibroblast growth factor receptor 1 (FGFR1) in prostate cancer (PCa) progression. We found that PCa cells with high FGFR1 expression increase metastases and that FGFR1 expression is increased in human PCa bone metastases, and identified genes that could participate in the metastases induced by FGFR1. These studies will help pinpoint PCa patients who use fibroblast growth factor to progress and will benefit by the inhibition of this pathway | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Bone metastasis | |
| 650 | 4 | |a Fibroblast growth factor receptor 1 | |
| 650 | 4 | |a Ladinin 1 | |
| 650 | 4 | |a Prostate cancer | |
| 650 | 7 | |a Fibroblast Growth Factors |2 NLM | |
| 650 | 7 | |a 62031-54-3 |2 NLM | |
| 650 | 7 | |a FGFR1 protein, human |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 650 | 7 | |a Receptor, Fibroblast Growth Factor, Type 1 |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 700 | 1 | |a Yang, Jun |e verfasserin |4 aut | |
| 700 | 1 | |a Shepherd, Peter D A |e verfasserin |4 aut | |
| 700 | 1 | |a Wan, Xinhai |e verfasserin |4 aut | |
| 700 | 1 | |a Starbuck, Michael W |e verfasserin |4 aut | |
| 700 | 1 | |a Guerra, Leah D |e verfasserin |4 aut | |
| 700 | 1 | |a Anselmino, Nicolas |e verfasserin |4 aut | |
| 700 | 1 | |a Bizzotto, Juan A |e verfasserin |4 aut | |
| 700 | 1 | |a Dong, Jiabin |e verfasserin |4 aut | |
| 700 | 1 | |a Chinnaiyan, Arul M |e verfasserin |4 aut | |
| 700 | 1 | |a Ravoori, Murali K |e verfasserin |4 aut | |
| 700 | 1 | |a Kundra, Vikas |e verfasserin |4 aut | |
| 700 | 1 | |a Broom, Bradley M |e verfasserin |4 aut | |
| 700 | 1 | |a Corn, Paul G |e verfasserin |4 aut | |
| 700 | 1 | |a Troncoso, Patricia |e verfasserin |4 aut | |
| 700 | 1 | |a Gueron, Geraldine |e verfasserin |4 aut | |
| 700 | 1 | |a Logothethis, Christopher J |e verfasserin |4 aut | |
| 700 | 1 | |a Navone, Nora M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European urology oncology |d 2018 |g 5(2022), 2 vom: 13. Apr., Seite 164-175 |w (DE-627)NLM285558595 |x 2588-9311 |7 nnns |
| 773 | 1 | 8 | |g volume:5 |g year:2022 |g number:2 |g day:13 |g month:04 |g pages:164-175 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.euo.2021.10.001 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 5 |j 2022 |e 2 |b 13 |c 04 |h 164-175 | ||